Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals has launched the first clinical site for its HG-CT-1 Phase I trial, targeting relapsed/refractory acute myeloid leukemia (AML) in adults. This trial, a dose-escalation study, aims to assess the safety and clinical impact of HG-CT-1, offering new hope to AML patients who have limited treatment options. The opening of this trial site marks a significant milestone for the company, potentially strengthening its position in the biopharmaceutical industry and impacting AML treatment approaches.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. It focuses on developing new medicines and treatments for blood and autoimmune diseases, aiming to extend the benefits of bone marrow transplantation to more patients with otherwise incurable diseases. The company is engaged in creating multiple product candidates and a platform technology for innovative product development.
YTD Price Performance: -57.45%
Average Trading Volume: 34,778
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £13.72M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.
